The genus Ganoderma includes a wide variety of worldwide wood-decaying fungi. It is well-recognized that these species can cause white rot in a wide range of tree varieties. Since ancient times, Ganoderma has been used as a medicinal mushroom in Asia. It offers a variety of pharmacological benefits, most notably in immunomodulation. It lives on decaying wood, and it is harvested for its mycelia, spores, and basidiocarps, which are then sold in a variety of forms, such as beverages, capsules, and powders. In recent years, the Ganoderma business has seen rapid expansion, driven by research and commercial initiatives. Numerous commercial goods have integrated bioactive materials and their pharmacological effects. More individuals are switching to dietary supplements and nutraceuticals to strengthen their immune systems and overall health, and the demand for Ganoderma mushrooms as a therapeutic agent is expected to rise shortly. The economic viability of reishi production is determined by a variety of factors, including the selection of high-yielding strains, the optimization of environmental parameters, and the application of effective resource management measures.